Serum Anti-heat Shock Protein 27 Antibody Titers in Patients With Dyslipidemia: A Population-based Case-control Study

authors:

avatar Fatemeh Sadabadi 1 , avatar Maryam Shahi ORCID 2 , avatar Susan Darroudi 3 , avatar Azam Rastgar Moghadam 3 , avatar Sahar Heidari-Bakavoli 4 , avatar Asma Porsa 3 , avatar Sara Saffar Soflaei 3 , avatar Habibollah Esmaily ORCID , avatar Mohsen Moohebati 5 , avatar Ghodratollah Salehi Sangani 6 , avatar Gordon A . Ferns , avatar Bibi Razieh Hoseini Farash ORCID 6 , avatar Majid Ghayour-Mobarhan ORCID 3 , *

Cutaneous Leishmaniasis Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Blood Borne Infections Research Center, Academic Center for Education, Culture and Research, Razavi Khorasan Branch, Mashhad, Iran.
Metabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Biology, School of Sciences, Ferdowsi University of Mashhad, Mashhad, Iran.
Cardiovascular Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Parasitology and Mycology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Journal of Inflammatory Diseases: Vol.26, issue 1; 1-8
article type: issue_documents_importer

how to cite: Sadabadi F, Shahi M, Darroudi S, Rastgar Moghadam A, Heidari-Bakavoli S, et al. Serum Anti-heat Shock Protein 27 Antibody Titers in Patients With Dyslipidemia: A Population-based Case-control Study. J Inflamm Dis. 2022;26(1):e156302. 

Abstract

Background: Heat shock protein 27 (HSP27) is found in several cell types of adults, such as cardiomyocytes, and endothelial cells. It is expressed in response to different cellular stress conditions. HSP27 decreases the levels of reactive oxygen species (ROS) and dyslipidemia is closely associated with increased endothelial production of reactive oxygen species (ROS).  Objective: Higher serum HSP27 antigen and anti-HSP27 antibodies have been reported in patients with unstable angina and myocardial infarction Methods: This population-based case-control study was conducted in 2018. We investigated serum anti-HSP27 antibody titers in all participants with dyslipidemia from the Mashhad stroke and heart atherosclerotic disorder (MASHAD) study (n=8141) and those who were healthy in terms of dyslipidemia (n=1637) using an in-house enzyme-linked immune sorbent assay (ELISA) in individuals with dyslipidemia. Findings: Anti-HSP27 titers were significantly lower in individuals with dyslipidemia compared to people without dyslipidemia (P=0.036). Conclusion: Our results revealed that the anti-HSP27 antibody titer was lower in the participants with dyslipidemia than in the negative group. However, there may be a confounding effect of drug therapy. In a subgroup of dyslipidemic subjects, we observed lower anti-HSP27 antibody titers in patients treated with some drugs (statins or corticosteroids, non-steroidal anti-inflammatory drugs [NSAIDs], or anti-diabetic and anti-hypertensive) compared to subjects untreated with these drugs.